- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, "Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer." In this comparative effectiveness study, immune checkpoint inhibitors were more effective than taxanes in patients with mCRPC when tumor mutational burden (TMB) was 10 mt/Mb...
|
- Details
- In this UroToday Journal Club, Drs Christopher Wallis and Zachary Klaassen present a Lancet Oncology publication titled Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Spinal cord compression is one of t...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer”. Dr. Wallis discusses DNA damage repair mutations and how they present in men with localized prostate cancer. They also discuss the specific genomic mutations seen most commonly in men with DNA damage repair mutations affecting their prosta...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss The Journal of Clinical Oncology publication entitled, "Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial." This trial evaluated the treatment effect of adding docetaxel to ADT + radiation therapy on the primary end point of overall...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the publication titled, "The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study." This trial aimed to determine whether the combination of PSMA + MRI was supe...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.” This study is investigating how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. This study shows that tumor classification by gene expression profiling and...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the KEYNOTE-057 study. The KEYNOTE-057 study sought to assess whether pembrolizumab could induce the clinical complete response in patients with BCG-unresponsive high-risk NMIBC. Standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guerin (BC...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a Lancet Oncology publication on the KEYNOTE-361 trial, pembrolizumab alone, or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma: A randomized open-label phase three trial. The authors of this trial assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemothe...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the CheckMate 274 publication, “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.” The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. The authors of this publication assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery t...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a paper entitled, “Randomized Phase 3 Trial of Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Advanced Urothelial Carcinoma.” Currently, the standard of care remains cisplatin-based chemotherapy without the addition of biologic agents. The addition of bevacizumab did not improve overall survival when added to gemcitabine and c...
|
